Relmada Therapeutics (RLMD) Shares Outstanding (Weighted Average) (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Shares Outstanding (Weighted Average) data on file, last reported at $86.6 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $86.6 million, up 184.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $86.6 million (up 184.77% YoY), and the FY2025 annual result was $4.2 million, down 86.04% from the prior year.
• Shares Outstanding (Weighted Average) grew to $86.6 million in Q1 2026 per RLMD's latest filing, from $4.2 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $86.6 million in Q1 2026 and troughed at $5417.0 in Q3 2022.
• A 5-year average of $28.7 million and a median of $30.1 million in 2023 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Weighted Average) jumped 555543.4% in 2023, then tumbled 86.04% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $29.6 million in 2022, then increased by 1.59% to $30.1 million in 2023, then climbed by 0.21% to $30.2 million in 2024, then plunged by 86.04% to $4.2 million in 2025, then jumped by 1956.68% to $86.6 million in 2026.
• Business Quant data shows RLMD's Shares Outstanding (Weighted Average) at $86.6 million in Q1 2026, $4.2 million in Q4 2025, and $33.2 million in Q3 2025.